What Is Amylin? Benefits, Research & Safety

Amylin was discovered in 1987 by Garth Cooper and colleagues, who isolated it from amyloid deposits in the pancreatic islets of patients with type 2 diabetes. The peptide was named for its tendency to form amyloid fibrils. Initial research focused on the potential role of amylin aggregation in beta cell dysfunction and type 2 diabetes pathophysiology. The amyloid deposits seen in diabetic islets were composed primarily of aggregated IAPP. Subsequent research revealed amylin's physiological functions as a hormone. Studies showed it complemented insulin by slowing gastric emptying, suppressing glucagon, and reducing food intake—all beneficial for glucose control. Recognition that amylin was deficient in diabetes (absolute in type 1, relative in type 2) suggested therapeutic potential for amylin replacement. However, human amylin's tendency to aggregate complicated drug development. Amylin Pharmaceuticals developed pramlintide, a modified amylin with three amino acid substitutions that prevent aggregation. Pramlintide (Symlin) received FDA approval in 2005 for use alongside insulin in type 1 and type 2 diabetes. Current development focuses on longer-acting amylin analogues and combination therapies. Cagrilintide (a long-acting amylin analogue) combined with semaglutide (GLP-1 agonist) is in advanced development for obesity and shows particularly promising weight loss results.